Importantly our results demonstrated that MCC950 treatment significantly reduced IL-1β, IL-1α, IL17, IL6, IFN-γ, TNF-α and MIP1a in the colitis colon (Fig. 6a–f)). This evidence concerns the gene IL6 and colitis.